A5027798156- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Neuroendocrine Tumor Research Advances
- Neuroblastoma Research and Treatments
- Advanced Breast Cancer Therapies
- Lung Cancer Research Studies
- PARP inhibition in cancer therapy
- Palliative Care and End-of-Life Issues
- Lung Cancer Diagnosis and Treatment
- Tumors and Oncological Cases
- Childhood Cancer Survivors' Quality of Life
- CAR-T cell therapy research
- Economic and Financial Impacts of Cancer
- Chemotherapy-induced cardiotoxicity and mitigation
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal Cancer Treatments and Studies
- Genital Health and Disease
- Cancer Genomics and Diagnostics
- Gastrointestinal disorders and treatments
- Breast Cancer Treatment Studies
- Toxin Mechanisms and Immunotoxins
- Testicular diseases and treatments
- Cancer Diagnosis and Treatment
- Family Support in Illness
- Cancer Treatment and Pharmacology
Instituto de Investigación Biomédica de Salamanca
2022-2025
Universidad de Salamanca
2022-2025
Palliative care focuses on improving the quality of life and comfort patients in last stages their disease by providing relief for pain other distressing symptoms, it integrates physical, psychological, spiritual aspects. The main objective this study is to assess impact palliative administration active treatment during 3 weeks with advanced non-small cell lung cancer (NSCLC) its survival after cycle. A retrospective was conducted across two centers, analyzing data from both sites evaluate...
Background/Objectives: Recent advances in the treatment of non-small cell lung cancer (NSCLC) have shifted from conventional chemotherapy to targeted therapies aimed at specific genetic mutations, particularly adenocarcinoma subtype. These improved overall survival and quality life. However, some patients still face barriers accessing these treatments due challenges diagnosing advanced-stage NSCLC. Limited tumor cellularity small biopsies cytological samples hinders ability perform further...
Introduction COVID-19 disease has caused a global health and economic crisis. The introduction of the different vaccines resulted in significant decrease morbidity mortality associated with this disease. Adverse effects have been reported, including cardiological ones such as myocarditis or pericarditis after administration. Likewise, tyrosine kinase inhibitor drugs osimertinib used lung cancer patients epidermal growth factor receptor (EGFR) mutation are heart failure prolongation QT...
Introduction: Immunotherapy represents a key pillar of cancer treatments, with high response rates and long survival. Its use is increasing, mainly at the expense geriatric population due to ageing this population. However, despite its benefit, safety in certain areas such as cardiotoxicity largely unknown. The aim study assess immunotherapy elderly patients using real-world data. Methods: This an ambispective ≥ 70 years old solid tumours who were treated University Hospital Salamanca....
In recent years, non-small cell lung cancer treatment has been revolutionized. EGFR tyrosine kinase inhibitors and our improved understanding of its alterations have driven new diagnostic strategies. Liquid biopsies emerged as a useful tool in these contexts, showing potential utility early diagnosis combined with low-dose CT scans, well monitoring response predicting the development patients. We studied circulating tumor DNA (ctDNA) 38 EGFR-mutated patients at different moments their...
Hepatoid gastric adenocarcinoma (HGA) is a rare subtype of cancer. It usually presents with non-specific digestive tract symptoms and diagnosed in advanced stages. has radiological histological similarities to hepatocarcinoma (HCC), serum elevation alpha-fetoprotein (AFP) characteristic, as positive staining for this marker on immunohistochemistry. Given the low incidence poor prognosis type tumour, it essential make correct differential diagnosis initiate early surgical treatment localised...
Immunotherapy has revolutionized the treatment of metastatic non-small cell lung cancer (NSCLC). However, there are still few studies that analyze impact poverty and depopulation on survival these patients. This single-center, ambispective study included patients diagnosed without first-line druggable mutation-free NSCLC between 2018 2023. Patients who received with immunotherapy (anti PD-1) alone or in combination chemotherapy were included. In primary outcome evaluated OS PFS according to...
Abstract Background: Activating mutations of PIK3CA gene are described in about 30-40% BC. They confer overall worse prognosis and resistance to endocrine chemotherapeutic therapy. Concordance between testing methods (tissue & plasma) not widely studied. We aim correlate tissue plasma assays analyze the discordant cases prognostic value (PIK3CAm) HR+/HER2- Methods: performed a retrospective unicentric analysis mutational status samples patients (pts) with BC from February/21 April/23....
Pancreatic adenocarcinoma is one of the most aggressive tumors. Its diagnosis usually made in locally advanced or metastatic disease and survival less than year. The frequent sites involvement are liver, peritoneum lungs. Other organs such as bones brain may be affected to a lesser extent. Cutaneous pancreatic extremely rare with 150 cases reported literature since 1960. Most cutaneous involve periumbilical region, lesion known "Sister Mary Joseph’s Node". Scalp metastases very their...